Dimensional Fund Advisors’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$891K Buy
855,724
+314,546
+58% +$648K ﹤0.01% 2852
2026
Q2
$1.18M Buy
541,178
+101,394
+23% +$299K ﹤0.01% 2828
2026
Q1
$2.32M Buy
439,784
+98,188
+29% +$567K ﹤0.01% 2669
2025
Q4
$1.83M Buy
341,596
+166,040
+95% +$767K ﹤0.01% 2751
2025
Q3
$619K Buy
175,556
+3,329
+2% +$10.5K ﹤0.01% 2957
2025
Q2
$447K Buy
172,227
+33,425
+24% +$68.9K ﹤0.01% 3013
2025
Q1
$264K Buy
138,802
+127,685
+1,149% +$340K ﹤0.01% 3095
2024
Q4
$16.1K Hold
11,117
– – ﹤0.01% 3330
2024
Q3
$20.5K Hold
11,117
– – ﹤0.01% 3334
2024
Q2
$11.1K Hold
11,117
– – ﹤0.01% 3365
2024
Q1
$22K Hold
11,117
– – ﹤0.01% 3364
2023
Q4
$17.3K Sell
11,117
-44
-0.4% -$76 ﹤0.01% 3394
2023
Q3
$22K Sell
11,161
-19,289
-63% -$47.7K ﹤0.01% 3438
2023
Q2
$96.8K Buy
+30,450
New +$95.6K ﹤0.01% 3327

Other funds holding CMPX

Dimensional Fund Advisors's CMPX Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Compass Therapeutics (CMPX) stake by 58% in Q3 2026, buying an estimated $648K and bringing the position to 855,724 shares worth $891K. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Dimensional Fund Advisors first reported a position in CMPX in Q2 2023 and has held it in 14 quarters since. The position peaked at $2.32M in Q1 2026. 33 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Dimensional Fund Advisors held 855,724 shares of Compass Therapeutics worth $891K as of Q3 2026.
  • Dimensional Fund Advisors bought 314,546 Compass Therapeutics shares in Q3 2026, an estimated $648K.
  • Compass Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #2852 holding.
  • Dimensional Fund Advisors first reported a position in Compass Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • Dimensional Fund Advisors's Compass Therapeutics position peaked at $2.32M in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.